Neuronal nicotinic acetylcholine receptor α4β2 and α6-containing subtypes (α4β2* and α6* nAChRs)

Neuronal nicotinic acetylcholine receptors (nAChRs) are pentameric ligand-gated ion channels that modulate the release of key neurotransmitters, including dopamine, GABA, and glutamate, throughout the central nervous system. The α4β2 and α6-containing subtypes (often designated as α4β2* and α6*) represent the high-affinity nicotinic binding sites in the brain and are predominantly localized on dopaminergic terminals within the mesolimbic and nigrostriatal pathways. These receptors are critical mediators of the rewarding effects of nicotine and the regulation of voluntary motor activity, making them primary therapeutic targets for smoking cessation and Parkinson's disease. In smoking cessation, partial agonists like varenicline are used to alleviate withdrawal while preventing the reinforcing spikes in dopamine caused by inhaled nicotine. Furthermore, these subtypes are implicated in the pathophysiology of depression, ADHD, and cognitive disorders due to their role in maintaining synaptic tone and plasticity. Current drug development efforts focus on achieving high selectivity for these neuronal subtypes over peripheral α3β4-containing receptors to minimize common side effects such as nausea and cardiovascular activation.

Other names

α4β2 nicotinic acetylcholine receptorα6-containing nicotinic acetylcholine receptorα4β2* nAChRα6β2* nAChRHigh-affinity heteromeric nicotinic receptorsCHRNA4-CHRNB2 receptorCHRNA6-CHRNB2-CHRNB3 receptor

Drugs targeting these receptors typically act as agonists, partial agonists, or antagonists to modulate ion channel opening and subsequent neurotransmitter release. Partial agonists like varenicline provide a dual mechanism by stimulating low-level dopamine release to reduce withdrawal symptoms while simultaneously blocking the binding of nicotine to prevent reinforcement. Antagonists or desensitizing agents may be used to inhibit overactive cholinergic signaling in conditions like depression or to study receptor function in neurodegeneration.